Financial health
- Operating income covered interest expense -642.8× in the latest year.
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
KPRX Financials KIORA PHARMACEUTICALS INC
9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $0 | -$10835 | — | — | -$10M | — | $9M |
| 2024 | $16M | $3595 | 0.0% | 28.2% | $9M | — | $4M |
| 2023 | $0 | -$12514 | — | — | -$10M | — | $2M |
| 2022 | — | -$14M | — | — | -$10M | — | $6M |
| 2021 | — | -$14M | — | — | -$11M | — | $8M |
| 2020 | — | -$7M | — | — | -$7M | $278190 | $1M |
| 2019 | — | -$7M | — | — | -$8M | $0 | $4M |
| 2018 | $2M | -$11M | 0.0% | -656.3% | -$11M | — | $8M |
| 2017 | $407518 | -$13M | 0.0% | 0.0% | -$7M | — | $8M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$2M | — | — | -$3M | — | $11M |
| Dec '25 | $0 | -$7M | — | — | -$2M | — | $9M |
| Sep '25 | $0 | $26806 | — | — | -$1M | — | $6M |
| Jun '25 | $0 | -$2M | — | — | — | — | $1M |
| Mar '25 | $0 | -$2M | — | — | -$3M | — | $4M |
| Dec '24 | $0 | -$4M | — | — | -$2M | — | $4M |
| Sep '24 | $0 | -$3M | — | — | $920057 | — | $6M |
| Jun '24 | $20000 | -$2M | 0.0% | -12724.4% | — | — | $7M |
| Mar '24 | $16M | $13M | 0.0% | 82.6% | — | — | $31M |
| Dec '23 | $0 | -$2M | — | — | -$3M | — | $2M |
| Sep '23 | $0 | -$6M | — | — | -$3M | — | $5M |
| Jun '23 | $0 | -$3M | — | — | — | — | $8M |
| Mar '23 | $0 | -$2M | — | — | — | — | $3M |
| Dec '22 | — | -$2M | — | — | — | — | $6M |
| Sep '22 | — | -$5M | — | — | — | — | $5M |
| Jun '22 | — | -$2M | — | — | — | — | $2M |
| Mar '22 | — | -$4M | — | — | — | — | $5M |
| Dec '21 | — | -$6M | — | — | -$3M | — | $8M |
| Sep '21 | — | -$3M | — | — | -$2M | — | $11M |
| Jun '21 | — | -$3M | — | — | -$3M | — | $4M |
Valuation over time
How the market has priced KPRX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 4129.9× (Dec '24) to 2441.0× (Nov '25).
- The price-to-sales ratio has fallen from 0.9× (Dec '24) to 0.5× (Nov '25).
P/E
P/S
Frequently asked questions
Is KPRX growing its revenue and profit?
See the revenue and net-income charts above for KIORA PHARMACEUTICALS INC's multi-year trend.
How much debt does KPRX have?
As of FY2025, KIORA PHARMACEUTICALS INC reported — of total debt against $9M of cash; operating income covered interest expense -642.8×.
What is KPRX's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is KPRX's P/E ratio?
As of Jun '26, KIORA PHARMACEUTICALS INC traded at a price-to-earnings ratio of about 2441.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.